Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.

Abstract:

INTRODUCTION:Sorafenib is a novel oral bis-aryl urea compound that has proven survival benefit in patients with advanced hepatocellular carcinoma (HCC), for which several therapies are currently available with unsatisfactory results. Sorafenib is the first compound to demonstrate a significant effect on survival in HCC. AREAS COVERED:Our experience in the clinical application of sorafenib is reviewed in conjunction with relevant publications in the literature. Based on ex vivo and in vivo experiments, we conclude that sorafenib plays an important role in blocking tumor cell proliferation, inducing apoptosis, and reversing multidrug resistance. Antitumor activities were observed in multiple tumor types in ongoing randomized Phase III studies. Toxicity was observed as tolerable. On 16 November 2007, sorafenib was approved by the United States Food and Drug Administration for the treatment of unresectable HCC, based on the results of an international, multicenter, randomized, double-blind, placebo-controlled trial in patients with unresectable, biopsy-proven HCC. EXPERT OPINION:With the approval of sorafenib being given the significance of a milestone, systemic treatment of HCC is no longer regarded as ineffective. The tyrosine kinase inhibitor, sorafenib, gives us new hope for successful cancer therapy.

authors

Guan YS,He Q

doi

10.1517/14656566.2011.546346

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

303-13

issue

2

eissn

1465-6566

issn

1744-7666

journal_volume

12

pub_type

杂志文章,评审
  • Sorafenib in liver cancer.

    abstract:INTRODUCTION:With growing knowledge of the molecular pathway of carcinogenesis, targeted therapies have become the 'blue ocean' of cancer treatment. sorafenib is an oral multikinase inhibitor that targets Raf/mitogen-activated protein (MAP) kinase/extracellular signal-regulated kinase (ERK) (Raf/MEK/ERK) and several ty...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.679930

    authors: Woo HY,Heo J

    更新日期:2012-05-01 00:00:00

  • Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.

    abstract::Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. HCM is characterized by a very complex pathophysiology, consisting of heterogeneous clinical manifestations a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1702023

    authors: Spoladore R,Fragasso G,Pannone L,Slavich M,Margonato A

    更新日期:2020-02-01 00:00:00

  • Review of vorapaxar for the prevention of atherothrombotic events.

    abstract:INTRODUCTION:Atherosclerosis is frequently caused by clot blockage of the coronary or peripheral arteries, and may lead to myocardial infarction (MI) or peripheral arterial disease (PAD). Despite advancements in management of atherosclerosis, mortality and ischemic rates remain high. Vorapaxar is a protease activated r...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1099629

    authors: Wang A

    更新日期:2015-01-01 00:00:00

  • Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.

    abstract:INTRODUCTION:Postprandial hyperglycemia (PPHG) contributes to micro- and macro-vascular complications more than fasting hyperglycemia in patients with type 2 diabetes mellitus. Due to the traditional carbohydrate-rich diet, Asians, particularly Indians and Chinese need agents to control the higher risk of uncontrolled ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1070827

    authors: Joshi SR,Standl E,Tong N,Shah P,Kalra S,Rathod R

    更新日期:2015-01-01 00:00:00

  • Drug-eluting stents for acute myocardial infarction.

    abstract::This is a review of the literature comparing the efficacy and safety of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with acute myocardial infarction (MI). The present article reviews whether DES are beneficial in the setting of primary percutaneous coronary intervention (PCI), and this has bee...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560802627952

    authors: Yeter E,Kurt M,Silay Y,Anderson HV,Denktas AE

    更新日期:2009-01-01 00:00:00

  • The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.

    abstract:OBJECTIVE:The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS:A total of 447 patients from 55 European centers who completed a 14-day screening and ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/14656566.2016.1190334

    authors: Bryson A,Jennings PE,Deak L,Paveliu FS,Lawson M

    更新日期:2016-07-01 00:00:00

  • Current and future therapies for gout.

    abstract:INTRODUCTION:Gout is a common disease responsible for recurrent flares triggered by the deposition of monosodium urate crystals secondary to longstanding hyperuricaemia. The management of gout implies both the treatment of flares and the treatment of hyperuricaemia itself. Recent improvement in the understanding of the...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1351945

    authors: Pascart T,Richette P

    更新日期:2017-08-01 00:00:00

  • Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study.

    abstract:BACKGROUND:The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with type 2 diabetes mellitus is unknown. METHODS:We conducted post hoc analyses of the results of a 52-week open-label study of Japanese type 2 diabetes mellitus patients treated with 100 or 200 ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1517/14656566.2015.1055250

    authors: Inagaki N,Goda M,Yokota S,Maruyama N,Iijima H

    更新日期:2015-01-01 00:00:00

  • Apremilast as a treatment for psoriasis.

    abstract:INTRODUCTION:Psoriasis is a common skin disorder characterized by chronic inflammatory lesions that are frequently vexing for patients and difficult for physicians to treat. Although multiple therapeutic options are available, all have limitations. Topical preparations have issues with patient adherence, as compared to...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.699959

    authors: Shutty B,West C,Pellerin M,Feldman S

    更新日期:2012-08-01 00:00:00

  • New treatment options for panic disorder: clinical trials from 2000 to 2010.

    abstract:INTRODUCTION:Panic disorder (PD) is a prevalent psychiatric disorder characterized by unexpected and recurrent panic attacks. PD patients present significant psychosocial impairment and a high risk of psychiatric comorbidities and suicide. PD should be treated effectively as soon as the symptoms emerge because the long...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.562200

    authors: Freire RC,Hallak JE,Crippa JA,Nardi AE

    更新日期:2011-06-01 00:00:00

  • TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept.

    abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.1.75

    authors: Mikuls TR,Moreland LW

    更新日期:2001-01-01 00:00:00

  • Nesiritide: a reappraisal of efficacy and safety.

    abstract::The treatment of acute decompensated heart failure (ADHF) remains a therapeutic challenge. Nesiritide was approved by the FDA in 2001 for the treatment of patients with ADHF who have dyspnea at rest or with minimal exertion. Although widely adopted for the treatment of ADHF due to its ability to decrease ventricular f...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.3.361

    authors: Shah SJ,Teerlink JR

    更新日期:2007-02-01 00:00:00

  • Pediatric HIV: new opportunities to treat children.

    abstract:BACKGROUND:Treating HIV-infected children remains a challenge due to a lack of treatment options, appropriate drug formulations and, in countries with limited resources, insufficient access to diagnostic tests and treatment. OBJECTIVE:To summarize current data concerning new opportunities to improve the treatment of H...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903012377

    authors: Van der Linden D,Callens S,Brichard B,Colebunders R

    更新日期:2009-08-01 00:00:00

  • Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia.

    abstract::Negative symptoms are core features of schizophrenia that respond poorly to first-generation antipsychotics and present a major obstacle in rehabilitation. Patients may be somewhat more responsive to clozapine and second-generation antipsychotics but even then, considerable impairment remains. This paper reviews the u...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.5.10.2053

    authors: Silver H

    更新日期:2004-10-01 00:00:00

  • The role of infectious agents in pulmonary and systemic vascular disease.

    abstract::With emphasis on the pulmonary circulation, three general types of vascular disease are discussed: fibroproliferative (atherosclerosis), cellular proliferative (endothelial neoplasms) and inflammatory (granulomatous vasculitis). The causes of these phenotypic responses are invariably multifactorial, but infectious age...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.7.1093

    authors: Egermayer P

    更新日期:2001-07-01 00:00:00

  • The role of Cediranib in ovarian cancer.

    abstract:INTRODUCTION:Treatment options for relapsed ovarian cancer have increased over the decade with the addition of targeted agents, such as PARP inhibitors and antiangiogenic agents. Bevacizumab, a monoclonal antibody binding vascular endothelial growth factor (VEGF), was the first anti-angiogenic agent to be incorporated ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1383384

    authors: Orbegoso C,Marquina G,George A,Banerjee S

    更新日期:2017-10-01 00:00:00

  • Pharmacotherapies for the treatment of glioblastoma - current evidence and perspectives.

    abstract:INTRODUCTION:Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COVERED:We reviewed the literature on gliob...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1176146

    authors: Seystahl K,Gramatzki D,Roth P,Weller M

    更新日期:2016-06-01 00:00:00

  • Thiazolidinediones: novel treatments for cognitive deficits in mood disorders?

    abstract::The aim of this review is to provide a rationale for evaluating thiazolidinediones (TZDs) as putative treatments for cognitive deficits in individuals with mood disorders. A MedLine search of all English-language articles published between January 1966 and August 2006 was conducted. The search terms were: the non-prop...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.11.1615

    authors: McIntyre RS,Soczynska JK,Woldeyohannes HO,Lewis GF,Leiter LA,MacQueen GM,Miranda A,Fulgosi D,Konarski JZ,Kennedy SH

    更新日期:2007-08-01 00:00:00

  • A comparative evaluation of properties and clinical efficacy of the echinocandins.

    abstract::With the increase in prevalence of fungal infections, newer antifungal agents are needed to effectively treat invasive disease, and at the same time minimize adverse effects from therapy. The echinocandins comprise a novel class of antifungals; their mechanism of action involves inhibiting 1,3-beta-D-glucan synthase, ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.10.1479

    authors: Kim R,Khachikian D,Reboli AC

    更新日期:2007-07-01 00:00:00

  • Daclatasvir for the treatment of chronic hepatitis C.

    abstract:INTRODUCTION:Following more than 20 years of Interferon (IFN)-based treatment for hepatitis C virus (HCV), the understanding of viral life cycle led to the development of new antiviral drugs directly targeting HCV replication steps. Daclatasvir (DCV) is a potent inhibitor of non-structural NS5A HCV protein with pangeno...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1109631

    authors: Degasperi E,Aghemo A,Colombo M

    更新日期:2015-01-01 00:00:00

  • Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer.

    abstract:INTRODUCTION:Tubulin inhibitors including taxanes and vinca alkaloids are important components of chemotherapy regimens used in advanced non-small cell lung cancer (NSCLC). Despite a treatment paradigm shift due to molecularly-targeted therapies and immunotherapy, a majority of patients will receive chemotherapy during...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1316374

    authors: Hardin C,Shum E,Singh AP,Perez-Soler R,Cheng H

    更新日期:2017-05-01 00:00:00

  • Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.

    abstract:BACKGROUND:Patients with rheumatoid arthritis (RA) have an increased risk of atherosclerotic cardiovascular disease which cannot be explained by traditional cardiovascular risk factors alone. Atherosclerosis is considered an inflammatory condition and inflammation experienced in RA may contribute to accelerated atheros...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.7.1121

    authors: Avouac J,Allanore Y

    更新日期:2008-05-01 00:00:00

  • Clinical management of chronic obstructive pulmonary disease and asthma in an obese patient.

    abstract::The prevalence of obesity has noticeably increased worldwide. The clinician is now frequently facing the challenge of managing patients with concomitant chronic obstructive pulmonary disease (COPD) or asthma and obesity. Obesity is often associated with a poorer control of these chronic respiratory diseases and the op...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.9.1.83

    authors: Lessard A,Maltais F,Boulet LP

    更新日期:2008-01-01 00:00:00

  • Does antipsychotic combination therapy reduce the risk of hospitalization in schizophrenia?

    abstract:INTRODUCTION:: Despite treatment with antipsychotic medication, approximately 1/3 of individuals with schizophrenia will fail to have an adequate response. To treat these patients, a commonly utilized approach is antipsychotic combination therapy. Antipsychotic combination therapy is controversial with mixed efficacy a...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1847274

    authors: Faden J,Kiryankova-Dalseth N,Barghini R,Citrome L

    更新日期:2020-11-30 00:00:00

  • Efavirenz: a review.

    abstract::Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.6.851

    authors: Vrouenraets SM,Wit FW,van Tongeren J,Lange JM

    更新日期:2007-04-01 00:00:00

  • Ezetimibe plus simvastatin for the treatment of hypercholesterolemia.

    abstract:INTRODUCTION:Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2015.1041504

    authors: Gryn SE,Hegele RA

    更新日期:2015-06-01 00:00:00

  • Pharmacotherapy of obstructive sleep apnea.

    abstract:INTRODUCTION:Obstructive sleep apnea syndrome is a common public health problem in the general population. The important health-related consequences of obstructive sleep apnea include cardiovascular disorders, such as myocardial infarction and hypertension, stroke, sudden death and difficult blood sugar control related...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.666525

    authors: Lin CM,Huang YS,Guilleminault C

    更新日期:2012-04-01 00:00:00

  • A new ketoconazole topical gel formulation in seborrhoeic dermatitis: an updated review of the mechanism.

    abstract::Seborrhoeic dermatitis (SD) is a chronic, inflammatory skin disorder, affecting areas of the head and body where sebaceous glands are most prominent and active. The disorder commonly affects hair-bearing areas of the head, including the scalp. Involvement on the face is usually limited to the hairline, eyebrows, nasol...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.8.9.1365

    authors: Faergemann J,Borgers M,Degreef H

    更新日期:2007-06-01 00:00:00

  • The pharmacological management of cardiovascular disease in people living with HIV (PLWH).

    abstract::ABSTARCT Introduction: Cardiovascular disease (CVD) continues to be an essential cause of morbidity and mortality among people living with human immunodeficiency virus infection (PLWH). Since the bulk of cardiovascular risk (CVR) factors are shared between PLWH and the general population, prevention and treatment stra...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2020.1856075

    authors: Corbacho N,Mur I,Molas ME,Vidal F,Domingo P

    更新日期:2021-01-04 00:00:00

  • A noninferiority confirmatory trial of prasugrel versus clopidogrel in Japanese patients with non-cardioembolic stroke: rationale and study design for a randomized controlled trial - PRASTRO-I trial.

    abstract:BACKGROUND:This comparison of PRAsugrel and clopidogrel in Japanese patients with ischemic STROke (PRASTRO)-I trial investigates the noninferiority of prasugrel to clopidogrel sulfate in the prevention of recurrence of primary events (ischemic stroke, myocardial infarction, and death from other vascular causes), and th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/14656566.2018.1444029

    authors: Nagao T,Toyoda K,Kitagawa K,Kitazono T,Yamagami H,Uchiyama S,Tanahashi N,Matsumoto M,Minematsu K,Nagata I,Nishikawa M,Nanto S,Abe K,Ikeda Y,Ogawa A

    更新日期:2018-04-01 00:00:00